<code id='6831D75832'></code><style id='6831D75832'></style>
    • <acronym id='6831D75832'></acronym>
      <center id='6831D75832'><center id='6831D75832'><tfoot id='6831D75832'></tfoot></center><abbr id='6831D75832'><dir id='6831D75832'><tfoot id='6831D75832'></tfoot><noframes id='6831D75832'>

    • <optgroup id='6831D75832'><strike id='6831D75832'><sup id='6831D75832'></sup></strike><code id='6831D75832'></code></optgroup>
        1. <b id='6831D75832'><label id='6831D75832'><select id='6831D75832'><dt id='6831D75832'><span id='6831D75832'></span></dt></select></label></b><u id='6831D75832'></u>
          <i id='6831D75832'><strike id='6831D75832'><tt id='6831D75832'><pre id='6831D75832'></pre></tt></strike></i>

          leisure time

          leisure time

          author:hotspot    Page View:3339
          Jeremey Wyatt ActiGraph

          As drugmakers wade into using digital health technologies, ActiGraph has made its mission to become the wearable of choice for the industry.

          The Pensacola, Fla.-based company creates  devices and software explicitly designed for clinical trials by focusing on features that matter to sponsors, like bulletproof reliability, access to raw sensor data, and 30-day battery life so that trial participants never have to worry about charging devices.

          advertisement

          There are many potential advantages to using wearables in clinical trials. Continuous data may collect a more comprehensive picture of how a patient responds to treatment and could help drugmakers complete trials faster with fewer participants. But risk-averse companies have been slow to adopt the technology and opt instead for the certainty of established methods for capturing data. The industry has yet to see a drug approved with evidence from a wearable device.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          Wikipedia

          Novavax promises a turnaround & Lilly roils the obesity market
          Novavax promises a turnaround & Lilly roils the obesity market

          SammyKimballforSTATCanNovavaxfinallygetitright?What’sa“triple-G”drug?AndisNovoNordisklosingground?We

          read more
          EMA weighs against approval for Mirati's lung cancer drug
          EMA weighs against approval for Mirati's lung cancer drug

          AdobeAEuropeanregulatorypanelhasrecommendedagainstapprovalofalungcancerdrugmadebyMiratiTherapeutics,

          read more
          Bright Health sells Medicare Advantage business to Molina
          Bright Health sells Medicare Advantage business to Molina

          BrightHealthisofficiallyleavingthehealthinsurancemarket.ThecompanyhasagreedtosellitsMedicareAdvantag

          read more

          Primary care physicians play key roles in Alzheimer's management

          AdobeWhentheresultsofPresidentBiden’sannualphysicalwerereleasedlastmonth,manywonderedwhyhisprimaryca